Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological...

Area of Science:

• Neonatal Pharmacology and Therapeutics
• Clinical Trial Design
• Regulatory Science

Background:

• Pediatric medication studies have increased, but neonatal therapeutic needs remain inadequately addressed.
• Existing global regulatory guidance lacks specificity for neonatal drug development, particularly for extremely premature infants.
• There is a critical need for improved guidelines to ensure safe and effective medication use in neonates.

Purpose of the Study:

• To develop a comprehensive White Paper to guide neonatal clinical trials, especially early-phase studies.
• To address the specific challenges and needs in neonatal drug development.
• To provide a framework for regulators, sponsors, and the neonatal community.

Main Methods:

• An international consortium, including neonatologists, nurses, parents, regulators, ethicists, and industry specialists, was formed.
• The consortium reviewed existing legislation, regulations, and guidance.
• A comprehensive, referenced White Paper was developed based on expert consensus and existing knowledge.

Main Results:

• The White Paper emphasizes basing product development on neonatal physiology and pharmacology.
• It highlights the central role of families in the research process.
• It underscores the value of the entire neonatal team in study design, implementation, and interpretation.

Conclusions:

• The developed White Paper provides essential guidance for conducting successful neonatal medicine clinical trials.
• It aims to inform and improve practices for regulators, sponsors, and healthcare professionals involved in neonatal care.
• Adherence to this guidance can enhance the development of safe and effective medications for the neonatal population.